Overall vaccine effectiveness of Pfizer-BioNTech COVID 19 mRNA vaccine is 95%

Objectives:
What is the overall vaccine effectiveness of the BNT162b2 mRNA vaccine (Pfizer-BioNTech COVID 19 mRNA vaccine) from observational studies?

Study design:
This review article included 19 observational studies.
The vaccine effectiveness was indicated as (pooled HR - 1)/HR or (pooled IRR - 1)/IRR.

Results and conclusions:   
The investigators found the meta-analysis revealed significant protective effect against RT-PCR confirmed COVID-19 ≥ 14 days after the first dose, with vaccine effectiveness of 53% [95% CI = 32% to 68%] and ≥ 7 days after the second dose, with vaccine effectiveness of 95% [95% CI = 96% to 97%].

The investigators concluded overall vaccine effectiveness of BNT162b2 mRNA vaccine (Pfizer-BioNTech COVID 19 mRNA vaccine) from observational studies is 95%. Despite its effectiveness, reporting vaccine safety data by relevant stakeholders should be encouraged as BNT162b2 mRNA is a new vaccine that has not gained full approval. There have been limited data about vaccine effectiveness among immunocompromised patients; thus, the vaccine should be used cautiously in this patient population.

Original title:
Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies by Kow CS and Hasan SS.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266992/

Additional information of El Mondo:
Find more information/studies on vaccination and coronavirus right here.